Br Med J 1977;1:739-741 (19 March), doi:10.1136/bmj.1.6063.739
Proliferative diabetic retinopathy: treatment with xenon-arc photocoagulation. Interim report of multicentre randomised controlled trial.
One hundred patients with symmetrical proliferative diabetic
retinopathy had one eye randomly chosen for treatment with xenonarc
photocoagulation while the other was left untreated as a control.
Patients were subdivided into those with new vessels on both
optic discs and those with only peripheral new vessels. In patients
with new vessels on the optic discs the vision of the untreated
eyes deteriorated more than that of the treated eyes and the
difference in deterioration was significant after one, two,
and three years. There was no such difference in patients who
had only peripheral new vessels. Eighteen patients had become
blind in one or both eyes by the last assessment, but only one
patient became blind in the treated eye without concomitant
blindness in the untreated eye. Thirteen were blind only in
the untreated eye. Both photographic and ophthalmoscopic examinations
showed that new vessels on the disc regressed more in the treated
eyes than in the untreated ones. As some forms of diabetic retinopathy
are now treatable, early diagnosis and evaluation is increasingly
important.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
This article has been cited by other articles:
-
Kohner, E. M
(2002). Review: Thirty-seven years with diabetic retinopathy. British Journal of Diabetes & Vascular Disease
2: 452-456
[Abstract]
-
Sorbinil Retinopathy Trial Research Group,
(1990). A Randomized Trial of Sorbinil, an Aldose Reductase Inhibitor, in Diabetic Retinopathy. Arch Ophthalmol
108: 1234-1244
[Abstract]